Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017

Eduard Kabasakalyan; Karapet Davtyan; Viktorya Cholakyans; Alvard Mirzoyan; Karine Kentenyants; Diana Petrosyan; Armen Hayrapetyan; Himanshu A Gupte

doi:10.3855/jidc.10920

Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017

Authors

Eduard Kabasakalyan National Tuberculosis Control Center, SNPO, MoH, Armenia
Karapet Davtyan FMD K and L Europe Contract Research Organization, Yerevan, Armenia
Viktorya Cholakyans National Tuberculosis Control Center, SNPO, MoH, Armenia
Alvard Mirzoyan National Tuberculosis Control Center, SNPO, MoH, Armenia
Karine Kentenyants FMD K and L Europe Contract Research Organization, Yerevan, Armenia
Diana Petrosyan UC Davis Health, Alzheimer ’s disease Center, Walnut Creek, California, United States
Armen Hayrapetyan National Tuberculosis Control Center, SNPO, MoH, Armenia
Himanshu A Gupte Narotam Sekhsaria Foundation, Mumbai, India

DOI:

https://doi.org/10.3855/jidc.10920

Keywords:

Tuberculosis, GeneXpert MTB/RIF, Diagnosis, NRL, Laboratory

Abstract

Introduction: In 2013, the National Tuberculosis (TB) Program of Armenia introduced GeneXpert MTB/RIF (Xpert) assay to address World Health Organization (WHO) target of 80% (2020) of notified new and relapse TB cases to be tested with WHO recommended rapid diagnostic methods. This study aimed to assess the change in laboratory diagnostic profile of Mycobacterium tuberculosis after introduction of the Xpert assay from 2013 to 2017.

Methodology: Retrospective cohort analysis of all presumptive TB patients’ records retrieved from the National Reference Laboratory database was performed.

Results: This study showed increased trend of Xpert coverage for suspected TB cases from 25% in 2013 to 86% in 2017 which is in line with WHO TB global strategy’s target of 80% in 2020. In 4.7% cases, Xpert tested positive while microscopy showed negative results. There was also an improved detection of Rifampicin resistance with increased concordance from 99.1% to 99.4% and decreased discordance from 6.7% to 1.4% between culture and Xpert results.

Conclusion: Armenia has achieved the 2020 target; in terms of utilizing the GeneXpert it is on track to achieve the End TB strategy target of 100% by 2025. The next step of this research will be assessment of the impact of GeneXpert and other TB tests utilization on the treatment outcomes in Armenia.

Downloads

Published

2019-05-16

How to Cite

Kabasakalyan E, Davtyan K, Cholakyans V, Mirzoyan A, Kentenyants K, Petrosyan D, Hayrapetyan A, Gupte HA (2019) Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017. J Infect Dev Ctries 13:022S-027S. doi: 10.3855/jidc.10920

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 13 No. 05.1: May 2019 - SUPPLEMENT

Section

The Armenian SORT IT Course

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).